Research programme: erythropoietin gene therapy - ARIAD

Drug Profile

Research programme: erythropoietin gene therapy - ARIAD

Alternative Names: AAV-mediated erythropoietin gene therapy - Ariad; Adeno-associated viral vector-mediated erythropoietin gene therapy - Ariad

Latest Information Update: 08 Nov 2006

Price : $50

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Antianaemics; Gene therapies; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Retinitis pigmentosa

Most Recent Events

  • 08 Nov 2006 Discontinued - Preclinical for Retinal disorders in Italy (unspecified route)
  • 08 Nov 2006 Discontinued - Preclinical for Retinal disorders in USA (unspecified route)
  • 23 Jun 2005 Preclinical trials in Retinal disorders in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top